Skip to main content

Table 6 Multivariate analyses of prognostic factors for disease-free survival and overall survival in patients with stage III colon cancer who received curative treatment

From: Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Variables Disease-free survival Variables Overall survival
HR (95% CI) P value HR (95% CI) P value
Age, year
(> 60 vs. ≤ 60)
1.787
(0.995–3.209)
0.052 T stage
(T4 vs. T1–3)
1.602
(0.465–5.520)
0.455
Gender
(male vs. female)
2.322
(1.201–4.492)
0.012 Risk stratification (high vs. low) 3.259
(0.654–6.236)
0.149
Adjuvant chemotherapy
(unfinished XELOX vs. modified XELOX)
1.448
(0.787–2.664)
0.235 Adjuvant chemotherapy
(unfinished XELOX vs. modified XELOX)
3.869
(1.515–9.880)
0.005
Preoperative serum CA19-9, U/mL
(> 24 vs. ≤ 24)
3.089
(1.654–5.770)
< 0.001 Preoperative serum CA19-9, U/mL
(> 24 vs. ≤ 24)
2.037
(0.946–4.387)
0.069
Preoperative serum CEA, ng/mL
(> 5 vs. ≤ 5)
1.147
(0.617–2.132)
0.666    
  1. XELOX oxaliplatin and capecitabine regimen, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, HR hazard ratio, CI confidence interval